Illustration: Assistant editor Kathy Wong for Endpoints News
Investors have pulled back from the biotech industry in recent months. But not Pablo Legorreta, who quietly pioneered a drug development niche that’s in demand.
Legorreta is the CEO and founder of Royalty Pharma, which is among a handful of specialty firms that buy future royalties for drugs that are approved or in late-stage clinical trials. In exchange, patent holders often get cash upfront, but in an amount that’s less than what they would otherwise receive over a royalty’s lifespan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
